Surgical Science Q1 2023: Strong across the board - Redeye

Redeye provides its initial take on Surgical Science’s Q1 2023 report, which exceeded our estimates in most regards. We judge that notable positives from the report include strong Education Products sales growth, EBITDA/EBIT margins coming in slightly above our estimates, and solid cash conversion. Notable negatives include a somewhat lower order backlog versus year-end 2022.

Länk till analysen i sin helhet: https://www.redeye.se/research/908391/surgical-science-q1-2023-strong-across-the-board?utm_source=finwire&utm_medium=RSS